medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2014, Number 4

<< Back Next >>

Rev Esp Med Quir 2014; 19 (4)

Failure in the eradication of Helicobacter pylori with empirical standard triple therapy in a population of Mexico

Sánchez-Cuén JA, Canizales-Román VA, León-Sicairos NM, Irineo-Cabrales AB, Peraza-Garay FJ, Monroy-Carreón L, Bernal-Magaña G

Language: Spanish
References: 23
Page: 415-422
PDF size: 674.16 Kb.


ABSTRACT

Background: Helicobacter pylori infection is recognized as a global problem. More than 50% of the world population is infected with this bacterium. Empirical standard triple therapy currently does not achieve acceptable cure rate in some countries. The aim of the study was to determine the eradication failure frequency of Helicobacter pylori infection with empirical standard triple therapy in a speciality hospital.
Methods: One cohort study was conducted on Sinaloa State workers with organic dyspepsia and Helicobacter pylori infection. Helicobacter pylori infection was diagnosed by culture, patients was treated with standard triple therapy for 14 days. 14C-urea breath test confirmed Helicobacter pylori eradication or eradication failure. Was used for statistical analysis the t student and Fisher exact test; was considered a significance of 0.05.
Results: We reviewed 77 subjects; the mean age of the subjects was 52.1 (SD 13.4) years. There were 62 women (80.5%) and 15 man (19.5%). 14C-urea breath test confirmed eradication failure in 5 (6.5 %) patients and eradication in 72 (93.5 %) patients. The most common endoscopic findings were erosive gastritis 24 (31.1 %), duodenitis 19 (24.7 %) and esophagitis in 19 (24.7 %), and the most common histopathological study findings were chronic gastritis 58 (75.3 %) and mucosa with minimal inflammatory changes in 11 (14.3 %).
Conclusion: Treatment with standard triple therapy is considered a successful regimen, provided not only the eradication of Helicobacter pylori infection in 6.5% in the study population.


REFERENCES

  1. Marshall B. Helicobacter connections. Chem Med Chem 2006; 1(8):783-802.

  2. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-1275.

  3. Muhammad JS, Zaidi SF, Sugiyama T. Epidemiological ins and outs of helicobacter pylori: a review. J Pak Med Assoc 2012; 62(9):955-959.

  4. Conteduca V, Sansonno D, Lauletta G, et al. H. pyloriinfection and gastric cancer: state of the art (review). Int J Oncol 2013;42(1):5-18.

  5. Bosques-Padilla FJ. Third Mexican Consensus on Helicobater pylori. Rev Gastroenterol Mex 2007;72(3):320.

  6. Torres J, Leal-Herrera Y, Perez-Perez G, et al. A community-based seroepidemiologic study of Helicobacter pylori infection in Mexico. J Infect Dis 1998;178(4):1089-1094.

  7. Castillo-Rojas G, Mazari-Hiriart M, Lopez-Vidal Y. Helicobacter pylori: focus on cagA and vacA major virulen cefactors. Salud Publica Mex 2004;46(6):538-548.

  8. Wroblewski L, Peek R, Wilson K. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev 2010;4:713-739.

  9. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186

  10. Torres J, Pérez-Pérez GI. Leal-Herrera Y, et al.Infection with CagA + Helicobacter pylori strains as a possible predictor of risk of gastric carcinoma in México. Int J Cancer 1998;78:298-300.

  11. Peek RM Jr, Thompson SA, Donahue JP, et al. Adherence to gastric epithelial cells induces expression of a Helicobacter pylorigene, iceA that is associated with clinicaloutcome. Proc Assoc Am Physicians 1998;110: 531-544.

  12. Malfertheiner P, Sipponen P, Naumann M, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005;100:2100-2115.

  13. Malfertheiner P, Megraud F, O’ Morain CA, et al. European- Helicobacter Study Group. Management of Helicobacter pylori infection. The Maastricht IV/Florence Consensus Report. Gut 2012;61(5):646-664.

  14. Sugimoto M, Yamaoka Y. Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp (Warsz) 2009;57:45-46.

  15. Graham DY, Fischbach DY. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59(8):1143-1153.

  16. González-Hueso MS, Rojas-Sánchez A, Rosales-Solís AA, et al.Helicobacter pylori eradication frequency with the conventional triple therapy in adult patients at the Centro Médico Issemym. Rev Gastroenterol Mex 2012;77(3):114- 118.

  17. Greenberg ER, Anderson GL, Morgan DR, et al.14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011;378(9790):507-14.

  18. Yakoob J, Abid S, Abbas Z, et al. Antibiotic susceptibility patterns of Helicobacter pylori and triple therapy in a highprevalence area. Br J Biomed Sci 2010;67(4):197-201.

  19. Songür Y, Senol A, Balkarli A, et al.Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment. Am J Med Sci 2009;338(1):50-53.

  20. Gopal R, Elamurugan TP, Kate V, et al.Standard triple versus levofloxacin based regimen for eradication of Helicobacter pylori. World J Gastrointest Pharmacol Ther 2013;6;4(2):23-27.

  21. Filipec Kanizaj T, Katitic M, Skurla B, et al. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole tripletherapy regimens. Helicobacter 2009;14(1):29-35.

  22. Camargo MC, García A, Riquelme A, et al.The problem ofHelicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 2014;109(4):485-95.

  23. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection a critical review. Aliment Pharmacol Ther 2004;20:1001-1017.




2020     |     www.medigraphic.com